Document:

EX-10.29

 Exhibit 10.29 
  

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 Funding Contract 

executed between the 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

as Funding Agency 
 and 

ARSANIS Biosciences GmbH 

Helmut-Qualtinger-Gasse 2 
 1030
Vienna 
 Company Register No. 354305m 

as Funding Recipient 
 § 1
Funding grant 
  

	1.1	On the basis of the funding application “Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections” received on 5/2/2013 via eCall, and based on the expert
decision of the Advisory Board in the meeting of 6/26/2013, funding is granted for the following project: 

 Project number:
841918 
 eCall number: 3875436 

Pre-project number: 837128 

Project name (purpose of the agreement): 

Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections 

Program:   Base program 

  
 ./2 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 Page 2 

§ 2 Project period 
  

	2.1	The overall project period shall begin on 5/13/2011 and end on 4/30/2014. 

  

	2.2	Funding of the entire project by the FFG depends on the results as demonstrated in the submitted reports, the continued fulfillment of the evaluation and decision criteria, the budget available to the Funding Agency and
a new positive funding decision. 

 § 3 Funding period 

 

	3.1	The funding period of this project shall begin on the approval date 5/1/2013 and end on 4/30/2014. 

§ 4 Type and amount of funding 
  

	4.1	Funding will be awarded in the following form over the funding period specified in § 3: 

  

									
	 Type of funding
	  	Maximum amount	 
	 Subsidy granted by the FFG
	  	 	EUR	 	  	 	585,300.00	 
	 Loan granted by the FFG
	  	 	EUR	 	  	 	2,503,000.00	 

 Loan conditions 
  

			
	 Interest rate
	  	 0.75% p.a. per current account

	 Redemption date:
	  	 6/30/2020

	 Redemption amount:
	  	 EUR 2,503,000.00

	 Interest and loan collection:
	  	 automatic debit procedure

	 Interest payment due:
	  	semi-annually in arrears and/or upon maturity of the loan

  

	4.2	The funded financing of the project is 70.0% of the verifiable and eligible project costs. The Funding Recipient shall finance the remaining project costs. Based on the plan data, the cash value of the funding is EUR
1,025,071.00, i.e. 23.2% related to the eligible project costs pursuant to Point 5.1. 

  

	4.3	The maximum funding cash value according to the applicable Community Framework for public R&D subsidies is 45.0%. 

  

	4.4	A decrease in the eligible project costs shall entail a prorated cutback of the funding. 

  

	4.5	The eligible project costs pursuant to § 5 and the costs reported by way of interim and/or final accounts shall not be considered approved until a review by the FFG. The final amount of the approved overall project
costs as well as the funding shall be determined only after the completion of the project in the course of the final audit. 

  
 ./3 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 Page 3 

§ 5 Eligible costs 
  

	5.1	The funding is based on following eligible project costs: 

  

									
	 Personnel costs
	  	 	EUR	 	  	 	959,600.00	 
	 Cost of use of R&D infrastructure
	  	 	EUR	 	  	 	36,300.00	 
	 Cost of materials
	  	 	EUR	 	  	 	300,000.00	 
	 Third-party costs
	  	 	EUR	 	  	 	3,093,200.00	 
	 Travel costs
	  	 	EUR	 	  	 	22,900.00	 
	 Total eligible costs
	  	 	EUR	 	  	 	4,412,000.00	 

  

	5.2	All costs attributable to the project which are incurred directly, actually and additionally to the normal operating expenses) for the duration of the funded research activities are eligible costs. Additional
supplementary provisions regarding eligible costs may be found in the FFG Guidelines, the FFG Guidelines Base Program and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”. 

 

	5.3	Major changes to the cost structure shall require the prior written approval of the FFG. 

  

	5.4	The turnover tax payable on the costs of eligible services is not an eligible cost. However, it is considered an eligible cost component if it can be demonstrated that said turnover tax must be borne in actual fact and
without recourse by the Funding Recipient, i.e. if it is not entitled to the input tax deduction. The refundable turnover tax—in whatever way—is not eligible even if it is not actually refunded to the Funding Recipient. If the tax office
considers funds which are taxable under the Turnover Tax Act 1994, Federal Gazette No. 663 not as funding but as a contractual compensation for services provided by the Funding Recipient to the Funding Agency, and if the Funding Recipient owes
turnover tax on such funds to the tax office, the contractual compensation shall be regarded as gross compensation. An additional, separate reimbursement of the turnover tax—for whatever legal reason—shall thus be excluded.

  

	5.5	If the amortization period of an asset (Sec. 285 ABGB [Allgemeines Bürgerliches Gesetzbuch (Civil Code)]) purchased for the implementation of the project exceeds the funding period, the depreciation costs
shall be eligible in the manner described in the FFG Guidelines – Base Program and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”. 

 

	5.6	Funds provided by the Funding Agency may not be used for the creation of reserves or accruals under the Income Tax Act 1988, Federal Gazette No. 400. The funds may be used only for goods and services and for the
purposes described in the funding application. 

  

	5.7	In case of new applications, the eligible costs incurred after receipt of the funding application may be approved. In case of follow-up applications, the earliest date for cost
approval shall be the beginning of the funding period stated under § 3. 

  

	5.8	The costs of drawing up the agreement or the bank transfer expenses incurred by the Funding Recipient or its affiliates shall be borne by them and shall not be eligible costs. 

  
 ./4 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 Page 4 
  

	5.9	The Funding Agency reserves the right to postpone, cut back or suspend the disbursement of funding if and as long as circumstances prevail which might make it impossible to guarantee the proper execution of the promoted
project (e.g. if the documentary evidence for costs is not adequate). 

 § 6 Project-specific terms and conditions

  

	6.1	Project-specific special terms and conditions 

  

	 	1.	Before the disbursement of the 1sr installment, the remaining funding must be documented in writing within 12 weeks from the issue date of the contract. 

 

	 	2.	“Other Services” shall not be funded. 

  

	 	3.	The cost for the preparation of the clinical phase (working packets 6 and 7) are funded with loans. 

  

	 	4.	A continued funding of this project in this form is not planned. The clinical work planned for the 4th project year may be submitted in the program line KLIPHA.

 § 7 Disbursement of the funds 
  

	7.1	The first installment in the amount of 50% of the promised funds will be disbursed after signature of the Funding Contract and fulfillment of the terms and conditions stipulated in § 6. 

The second installment in the amount of 30% will be disbursed after the approval of an interim report and an interim statement in which 50% of
the approved total costs must be documented, as well as after fulfillment of the terms and conditions stipulated in 
 § 6. 

The final installment in the amount of 20% of the total promised funds will be disbursed only after fulfillment of all terms and conditions
(final account, final reports, etc.) and after the audit and approval of the statement of use (discharge) by the FFG. 
  

	7.2	The funds will be transferred to the following account of the Funding Recipient 

  

			
	Account holder:	 	ARSANIS Biosciences GmbH
	Name of the bank:	 	
	IBAN:	 	
	BIC/SWIFT:	 	

 § 8 Reporting obligations 
  

	8.1	According to Point 3 of the General Funding Terms and Conditions, the Funding Recipient must inform the FFG about the execution of the promoted project by submitting technical reports (interim and final reports) and
billing statements. The reports and billing statements must be submitted via eCall (https://ecall.ffg.at). The use of the forms to be found in eCall is mandatory. Other documents might have to be submitted at the request of the FFG.

 § 9 Amendments 
  

	9.1	Changes to this agreement may be made only explicitly and in writing. This shall apply also to any deviation from this requirement. 

  
 ./5 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 Page 5 
  

	9.2	Under special circumstances changes to the stipulated terms and conditions may, if necessary, be made later by mutual agreement in the form of written addenda if special circumstances are present and after a new
advisory board decision. 

 § 10 Legal liability 

 

	10.1	The Funding Recipient shall be unconditionally liable to the FFG for compliance with all contractual provisions. The Funding Recipient shall also be liable for the conduct of third parties for which it is responsible
(e.g. owners, corporate officers, etc.). The Funding Recipient must hold the FFG harmless against third parties. 

 §
11 Severability clause 
  

	11.1	In the event that be a provision of this Funding Contract is invalid, such event shall not affect the validity of the remaining provisions of the Funding Contract. The contractual partners undertake to replace an
invalid provision by such provision as comes closest to the purpose of this Funding Contract. 

 § 12 Applicable law

  

	12.1	This agreement and all its attachments shall be governed by Austrian law to the exclusion of the reference norms of the Austrian IPRG. 

§ 13 Legal venue 
  

	13.1	The legal venue agreed upon with regard to all legal disputes arising from the funding grant shall be the materially competent court in Vienna. The FFG reserves the right to take action against the Funding Recipient
also at the latter’s general legal venue. 

 § 14 Integral parts of the contract 

 

	14.1	The following documents are an integral part of the Funding Contract: 

  

	 	•	 	The funding application submitted via eCall (“Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections”) as amended on 5/2/2013 

 

	 	•	 	General terms and conditions for Funding Contracts as amended (version 1 of 2013) 

  

	 	•	 	FFG Guidelines – Base Programs as amended (3/22/2012) 

  

	 	•	 	Guide for the Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG Directives, version 1.3. 

14.2 The legal bases of this Funding Contract are in particular: 
  

	 	•	 	Implementation Act of the Österreichische Forschungsförderungsgesellschaft mbH (Research Promotion Structural Reform Act), as amended 

 

	 	•	 	Guidelines of the Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines GZ: BMVIT 609.986/0005- 

  
 ./6 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 Page 6 

III/12/2008 and BMWA-98.310/0032-C1/10/2008) 

The Funding Recipient confirms being aware of all contract components and accepts them unconditionally. 

It is pointed out that this funding offer is considered revoked if the Funding Recipient does not sign it and return it to the FFG within 3 months. 

For the Funding Agency: 
 Österreichische
Forschungsförderungsgesellschaft mbH (FFG) 
 [stamp:] Austrian Research Promotion Agency 

Vienna, on 7/1/2013 
  

			
	 /s/ Dr. Henrietta Egerth-Stadlhuber
	 	 /s/ Dr. Klaus Pseiner

	 Dr. Henrietta Egerth-Stadlhuber

Director
	 	 Dr. Klaus Pseiner

Director

 Funding Recipient 
  

			
	 Vienna, on 8/6/2013
	  	 ARSANIS

		  	 Biosciences GmbH

		  	 MarxBox

		  	 Helmut-Qualtinger—Gasse 2

		  	 1030 Vienna

  

			
		 	 /s/ Dr. Eszter Nagy

		 	(company name, please indicate name and position in block letters, company seal)
		 	Dr. Eszter Nagy, Director

 Attachments: 
 Guidelines for the
Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines) per link https://www.ffg.at/Allgemeine-Richtlinien 

General terms and conditions for Funding Contracts as amended (version 1 of 2013) 

FFG Guidelines – Base Programs, as amended (3/22/2012) 

Guide for the Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG
Directives, version 1.3. 

  
 ./7 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 12/31/2013 

Project 841918 
 Development of human monoclonal antibody-based
products against severe hospital-associated bacterial infections 
  

			
	 Account no.:
	  	18419180
	 Fiscal year:
	  	2013
	 Redemption amount (EUR):
	  	1,244,928.00
	 Date of redemption:
	  	6/30/2020
	 Interest rate:
	  	0.75%

  

					
		  	Balance per 12/31/2013 (EUR)	  	0.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	3/10/2013	  	841918 DA Installment 1 GP basis	  	-1,251,500.00
	12/2/2013	  	841918 Int. 0.75% per 12/31/13	  	-2,324.00
	12/31/2013	  	841918 Int. 0.75% per 12/31/13	  	2,324.00
			
		  	Debited amount (EUR)	  	1,253,824.00
		  	Deposited amount (EUR)	  	2,324.00
			
		  	Balance per 12/31/2014 (EUR)	  	-1,251,500.00

  
 ./8 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 12/31/2014 

Project 841918 
 Development of human monoclonal antibody-based
products against severe hospital-associated bacterial infections 
  

			
	 Account no.:
	  	18419180
	 Fiscal year:
	  	2014
	 Redemption amount (EUR):
	  	1,244,928.00
	 Date of redemption:
	  	6/30/2020
	 Interest rate:
	  	0.75%

  

					
		  	Balance per 12/31/2013 (EUR)	  	-1,251,500.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	6/2/2014	  	841918 Int. 0.75% per 6/30/14	  	 -4,723.00

	6/30/2014	  	841918 Int. 0.75% per 6/30/14	  	 4,723.00

	7/10/2014	  	841918 Amortization	  	 6,572.00

	12/1/2014	  	841918 Int. 0.75% per 12/31//14	  	 -4,778.00

	12/31/2014	  	841918 Int. 0.75% per 12/31/14	  	 4,778.00

			
		  	Debited amount (EUR)	  	 9,501.00

		  	Deposited amount (EUR)	  	 16,073.00

			
		  	Balance per 12/31/2014 (EUR)	  	 -1,244,928.00

  
 ./9 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 10/31/2015 

Project 841918 
 Development of human monoclonal antibody-based
products against severe hospital-associated bacterial infections 
  

			
	 Account no.:
	  	18419180
	 Fiscal year:
	  	2015
	 Redemption amount (EUR):
	  	1,244,928.00
	 Date of redemption:
	  	6/30/2020
	 Interest rate:
	  	0.75%

  

					
		  	Balance per 12/31/2014 (EUR)	  	-1,244,928.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	6/1/2015	  	841918 Int. 0.75% per 6/30/15	  	-4,698.00
	6/30/2015	  	841918 Int. 0.75% per 6/30/15	  	4,698.00
			
		  	Debited amount (EUR)	  	4,698.00
		  	Deposited amount (EUR)	  	4,698.00
			
		  	Balance per 12/31/2015 (EUR)	  	-1,244,928.00

  
 ./10 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 841918/30000 SCK/SAI 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 12/31/2014 

Project 841918 
 Development of human monoclonal antibody-based
products against severe hospital-associated bacterial infections 
  

			
	Account no.:	  	28419180
	Fiscal year:	  	2014
	Reclaim (EUR):	  	0

  

					
		  	Balance per 12/31/2013 (EUR)	  	 0.00

			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	7/7/2014	  	841918 FB reclaims	  	 -1,537.00

	7/7/2014	  	841918 FB interest	  	 -10.00

	7/10/2014	  	841918 FB redemption	  	 1,537.00

	7/10/2014	  	841918 FB interest	  	 10.00

			
		  	Debited amount (EUR)	  	 1,547.00

		  	Deposited amount (EUR)	  	 1,547.00

			
		  	Balance per 12/31/2014 (EUR)	  	 0.00

  
 ./11 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax +43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
ViennaEX-10.30

 Exhibit 10.30 
  

 FFG         

Project no. 845382/30000 SCK/SAI 
  

 Funding Contract 

executed between the 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

as Funding Agency 
 and 

ARSANIS Biosciences GmbH 

Helmut-Qualtinger-Gasse 2 
 1030
Vienna 
 Company Register No. 354305m 

as Funding Recipient 
 § 1
Funding grant 
  

	1.1	On the basis of the funding application “Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections” received on 2/13/2014 via eCall, and based on the
expert decision of the Advisory Board in the meeting of 3/19/2014, funding is granted for the following project: 

 Project
number: 845382 
 eCall number: 3905280 

Pre-project number: 841918 

Project name (purpose of the agreement): 

Development of human monoclonal antibody-based products against severe 

hospital-associated bacterial infections 

Program:           Base program 

  
 ./2 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 845382/30000 SCK/SAI 
  

 Page 2 

§ 2 Project period 
  

	2.1	The overall project period shall begin on 5/13/2011 and end on 5/31/2015. 

  

	2.2	Funding of the entire project by the FFG depends on the results as demonstrated in the submitted reports, the continued fulfillment of the evaluation and decision criteria, the budget available to the Funding Agency and
a new positive funding decision. 

 § 3 Funding period 

 

	3.1	The funding period of this project shall begin on the approval date 2/1/2014 and end on 1/31/2015. 

§ 4 Type and amount of funding 
  

	4.1	Funding will be awarded in the following form over the funding period specified in § 3: 

  

					
	 Type of funding
	  	Maximum amount	 
	 Subsidy granted by the FFG
	  	EUR	 1,624,400.00	 
	 Loan granted by the FFG
	  	EUR	 1,821,300.00	 

 Loan conditions 

Interest rate
                               0.75% p.a. per current account 

Redemption date:                      
6/30/2020 
 Redemption amount:                  EUR
1,821,300.00 
 Interest and loan collection:       automatic debit procedure 

Interest payment due:                 semi-annually in arrears
and/or upon maturity of the loan 
  

	4.2	The funded financing of the project is 70.0% of the verifiable and eligible project costs. The Funding Recipient shall finance the remaining project costs. Based on the plan data, the cash value of the funding is EUR
1,706,871.00, i.e. 34.7% related to the eligible project costs pursuant to Point 5.1. 

  

	4.3	The maximum funding cash value according to the applicable Community Framework for public R&D subsidies is 45.0%. 

  

	4.4	A decrease in the eligible project costs shall entail a prorated cutback of the funding. 

  

	4.5	The eligible project costs pursuant to § 5 and the costs reported by way of interim and/or final accounts shall not be considered approved until a review by the FFG. The final amount of the approved overall project
costs as well as the funding shall be determined only after the completion of the project in the course of the final audit. 

  
 ./2 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 845382/30000 SCK/SAI 
  

 Page 3 

§ 5 Eligible costs 
 5.1
    The funding is based on following eligible project costs: 
  

									
	 Personnel costs
	  	 	EUR	 	  	 	1,189,600.00	 
	 Cost of use of R&D infrastructure
	  	 	EUR	 	  	 	116,300.00	 
	 Cost of materials
	  	 	EUR	 	  	 	440,000.00	 
	 Third-party costs
	  	 	EUR	 	  	 	3,156,600.00	 
	 Travel costs
	  	 	EUR	 	  	 	20,000.00	 
	 Total eligible costs
	  	 	EUR	 	  	 	4,922,500.00	 

  

	5.2	All costs attributable to the project which are incurred directly, actually and additionally to the normal operating expenses) for the duration of the funded research activities are eligible costs. Additional
supplementary provisions regarding eligible costs may be found in the FFG Guidelines, the Guide Individual Project of Experimental Development and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”.

  

	5.3	Major changes to the cost structure shall require the prior written approval of the FFG. 

  

	5.4	The turnover tax payable on the costs of eligible services is not an eligible cost. However, it is considered an eligible cost component if it can be demonstrated that said turnover tax must be borne in actual fact and
without recourse by the Funding Recipient, i.e. if it is not entitled to the input tax deduction. The refundable turnover tax—in whatever way—is not eligible even if it is not actually refunded to the Funding Recipient. If the tax office
considers funds which are taxable under the Turnover Tax Act 1994, Federal Gazette No. 663 not as funding but as a contractual compensation for services provided by the Funding Recipient to the Funding Agency, and if the Funding Recipient owes
turnover tax on such funds to the tax office, the contractual compensation shall be regarded as gross compensation. An additional, separate reimbursement of the turnover tax—for whatever legal reason—shall thus be excluded.

  

	5.5	If the amortization period of an asset (Sec. 285 ABGB [Allgemeines Bürgerliches Gesetzbuch (Civil Code)]) purchased for the implementation of the project exceeds the funding period, the depreciation costs
shall be eligible in the manner described in the Guide Individual Project of Experimental Development and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”. 

 

	5.6	Funds provided by the Funding Agency may not be used for the creation of reserves or accruals under the Income Tax Act 1988, Federal Gazette No. 400. The funds may be used only for goods and services and for the
purposes described in the funding application. 

  

	5.7	In case of new applications, the eligible costs incurred after receipt of the funding application may be approved. In case of follow-up applications, the earliest date for cost
approval shall be the beginning of the funding period stated under § 3. 

  

	5.8	The costs of drawing up the agreement or the bank transfer expenses incurred by the Funding Recipient or its affiliates shall be borne by them and shall not be eligible costs. 

  
 ./3 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 845382/30000 SCK/SAI 
  

 Page 4 
  

	5.9	The Funding Agency reserves the right to postpone, cut back or suspend the disbursement of funding if and as long as circumstances prevail which might make it impossible to guarantee the proper execution of the promoted
project (e.g. if the documentary evidence for costs is not adequate). 

 § 6 Project-specific terms and conditions

  

	6.1	Project-specific special terms and conditions 

  

	 	1.	The travel costs were cut back overall. 

  

	 	2.	Only costs for the new patent applications in the maximum amount of € 10,000 will be funded. 

§ 7 Disbursement of the funds 
  

	7.1	The first installment in the amount of 50% of the promised funds will be disbursed after signature of the Funding Contract and fulfillment of the terms and conditions stipulated in § 6. 

The second installment in the amount of 30% will be disbursed after the approval of an interim report and an interim statement in which 50% of
the approved total costs must be documented, as well as after fulfillment of the terms and conditions stipulated in § 6. 
 The
final installment in the amount of 20% of the total promised funds will be disbursed only after fulfillment of all terms and conditions (final account, final reports, etc.) and after the audit and approval of the statement of use (discharge) by the
FFG. 
  

	7.2	The funds will be transferred to the following account of the Funding Recipient 

 Account
holder:                 ARSANIS Biosciences GmbH 
 Name of
the bank:              
 IBAN:
                                

BIC/SWIFT:                       

§ 8 Reporting obligations 
  

	8.1	According to Point 3 of the General Funding Terms and Conditions, the Funding Recipient must inform the FFG about the execution of the promoted project by submitting technical reports (interim and final reports) and
billing statements. The reports and billing statements must be submitted via eCall (https://ecall.ffg.at). The use of the forms to be found in eCall is mandatory. Other documents might have to be submitted at the request of the FFG.

 § 9 Amendments 
  

	9.1	Changes to this agreement may be made only explicitly and in writing. This shall apply also to any deviation from this requirement. 

  

	9.2	Under special circumstances changes to the stipulated terms and conditions may, if necessary, be made later by mutual agreement in the form of written addenda if special circumstances are present and after a new
advisory board decision. 

  
 ./4 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 845382/30000 SCK/SAI 
  

 Page 5 

§ 10 Legal liability 
  

	10.1	The Funding Recipient shall be unconditionally liable to the FFG for compliance with all contractual provisions. The Funding Recipient shall also be liable for the conduct of third parties for which it is responsible
(e.g. owners, corporate officers, etc.). The Funding Recipient must hold the FFG harmless against third parties. 

 §
11 Severability clause 
  

	11.1	In the event that be a provision of this Funding Contract is invalid, such event shall not affect the validity of the remaining provisions of the Funding Contract. The contractual partners undertake to replace an
invalid provision by such provision as comes closest to the purpose of this Funding Contract. 

 § 12 Applicable law

  

	12.1	This agreement and all its attachments shall be governed by Austrian law to the exclusion of the reference norms of the Austrian IPRG. 

§ 13 Legal venue 
  

	13.1	The legal venue agreed upon with regard to all legal disputes arising from the funding grant shall be the materially competent court in Vienna. The FFG reserves the right to take action against the Funding Recipient
also at the latter’s general legal venue. 

 § 14 Integral parts of the contract 

 

	14.1	The following documents are an integral part of the Funding Contract: 

  

	 	•	 	The funding application submitted via eCall (“Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections”) as amended on 2/13/2014 

 

	 	•	 	General terms and conditions for Funding Contracts as amended (version 1 of 2013) 

  

	 	•	 	Guide Individual Projects of Experimental Development, version 1.0 

  

	 	•	 	Guide for the Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG Directives, version 1.3. 

 

	14.2	The legal bases of this Funding Contract are in particular: 

  

	 	•	 	Implementation Act of the Österreichische Forschungsförderungsgesellschaft mbH (Research Promotion Structural Reform Act), as amended 

 

	 	•	 	Guidelines of the Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines GZ: BMVIT
609.986/0005-III/12/2008 and BMWA-98.310/0032-C1/10/2008) 

  
 ./5 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 845382/30000 SCK/SAI 
  

 Page 6 
 The
Funding Recipient confirms being aware of all contract components and accepts them unconditionally. 
 It is pointed out that this funding offer is
considered revoked if the Funding Recipient does not sign it and return it to the FFG within 3 months. 
 For the Funding Agency: 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

[stamp:] Austrian Research Promotion Agency               

Vienna, on 3/24/2014 
  

							
	 /s/ Dr. Henrietta Egeth-Stadlhuber
	 		  	 /s/ Dr. Klaus Pseiner
	  	
	Dr. Henrietta Egerth-Stadlhuber	 		  	Dr. Klaus Pseiner	  	
	Director	 		  	Director	  	

 Funding Recipient 
  

							
	Vienna, on 4/3/2014	 		  	            ARSANIS	  	
		 		  	            Biosciences GmbH	  	
		 		  	            MarxBox	  	
		 		  	            Helmut-Qualtinger-Gasse 2	  	
		 		  	            1030 Vienna	  	

  

					
	 /s/ Estzer Nagy
	 		 	
	(company name, please indicate name and position in block letters, company seal)
	Dr. Eszter Nagy, Director

 Attachments: 
 Guidelines for the
Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines) per link https://www.ffg.at/Allgemeine-Richtlinien 

General terms and conditions for Funding Contracts as amended (version 1 of 2013) 

Guide Individual Projects of Experimental Development, version 1.0 

Guide for the Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG
Directives, version 1.3. 

  
 ./6 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 845382/30000 SCK/SAI 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 12/31/2014 

Project 845382 
 Development of human monoclonal antibody-based
products against severe hospital-associated bacterial infections 
  

					
	 Account no.:
	  	 	18453820	 
	 Fiscal year:
	  	 	2014	 
	 Redemption amount (EUR):
	  	 	1,634,932.00	 
	 Date of redemption:
	  	 	6/30/2020	 
	 Interest rate:
	  	 	0.75	% 

  

					
		  	Balance per 12/31/2013 (EUR)	  	0.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	 4/10/2014
	  	845382 DA Installment 1 GP basis	  	-910,650.00
			
	 6/2/2014
	  	845382 Int. 0.75% per 6/30/14	  	-1,541.00
			
	 6/30/2014
	  	845382 Int. 0.75% per 6/30/14	  	1,541.00
			
	 12/1/2014
	  	845382 Int. 0.75% per 12/31/14	  	-3,495.00
			
	 12/4/2014
	  	845382 DA Installment 2 GP basis	  	-546,390.00
			
	 12/31/2014
	  	845382 Int. 0.75% per 12/31/14	  	3,495.00
			
		  	Debited amount (EUR)	  	1,462,076.00
			
		  	Deposited amount (EUR)	  	5,036.00
			
		  	Balance per 12/31/2014 (EUR)	  	-1,457,040.00

  
 ./7 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 845382/30000 SCK/SAI 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 12/31/2015 

Project 845382 
 Development of human monoclonal antibody-based
products against severe hospital-associated bacterial infections 
  

					
	 Account no.:
	  	 	18453820	 
	 Fiscal year:
	  	 	2015	 
	 Redemption amount (EUR):
	  	 	1,634,932.00	 
	 Date of redemption:
	  	 	6/30/2020	 
	 Interest rate:
	  	 	0.75	% 

  

					
		  	Balance per 12/31/2014 (EUR)	  	-1,457,040.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	6/1/2015	  	845382 Int. 0.75% per 6/30/15	  	-5,498.00
			
	6/30/2015	  	845382 Int. 0.75% per 6/30/15	  	5,498.00
			
	8/20/2015	  	845382 DA Installment 3 GP basis	  	-177,892.00
			
		  	Debited amount (EUR)	  	183,390.00
			
		  	Deposited amount (EUR)	  	5,498.00
			
		  	Balance per 10/31/2015 (EUR)	  	-1,634,932.00

  
 ./8 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]